Morning Research: Ariad Pharma Inc., MannKind Corp., Novavax Inc., and Galena Biopharma Inc. PR Newswire LONDON, November 1, 2013 LONDON, November 1, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Thursday, October 31, 2013, all three indexes of the US equity market edged lower. The S&P 500 ended the day at 1,756.55, down 0.38%; the Dow Jones Industrial Average closed at 15,545.75, down 0.47%; and the NASDAQ Composite finished at 3,919.71, down 0.28%. Shares in the biotechnology industry mostly ended on a lower note, tracking losses in the broader market. The major movers in the industry included Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), MannKind Corp. (NASDAQ: MNKD), Novavax Inc. (NASDAQ: NVAX), and Galena Biopharma Inc. (NASDAQ: GALE). AAAResearchReports.com has released full comprehensive research on ARIA, MNKD, NVAX, and GALE. These free technical analyses can be downloaded by signing up at: http://www.aaaresearchreports.com/register/ Ariad Pharmaceuticals Inc.'s stock plummeted on Thursday, tracking losses in broader market. The company's shares closed the day at$2.20, down 44.44%, after oscillating between$2.15 and $2.59 during the trading session. A total of 64.97 million shares were traded, which is significantly above the daily average volume of 9.08 million. The company's shares have lost 46.47% in the previous three trading sessions, compared to a loss of 0.32% in the S&P 500 during the same period. Furthermore, Ariad Pharmaceuticals Inc.'s stock is trading below its 50-day and 200-day moving averages of $14.59 and $17.85, respectively. Download free report on ARIA upon registration at: http://www.AAAResearchReports.com/ARIA110113.pdf On Thursday, MannKind Corp.'s stock ended the day at $4.91, which is 0.30% lower than the previous day's closing price of $4.92. The company's shares fluctuated between $4.77 and $5.11 during the trading session. A total of 5.93 million shares were traded, which is below the daily average volume of 7.28 million. The company's shares have declined 6.39% in the previous trading sessions, underperforming the S&P 500, which has lost 0.32% during the same period. Moreover, MannKind Corp.'s stock is trading below its 50-day and 200-day moving averages of $5.61 and $5.11, respectively. MNKD technical report can be accessed for free by signing up at: http://www.AAAResearchReports.com/MNKD110113.pdf Novavax Inc.'s stock fluctuated between gains and losses before finishing the day flat on Thursday. The company's shares ended the session atthe previous day's closing price of $3.10, after fluctuating between$2.96 and$3.16 during the trading session. A total of 8.64 million shares were traded, which is above the daily average volume of 3.04 million. The company's shares have gained 8.98% in the previous three trading sessions and 15.06% in the last three months, compared to a loss of 0.32% and a gain of 4.20% in the S&P 500 during the respective periods. Additionally, Novavax Inc.'s stock is trading above its 200-day moving average of $2.41. The free report on NVAX can be downloaded by signing up now at: http://www.AAAResearchReports.com/NVAX110113.pdf Galena Biopharma Inc.'s stock advanced 2.06% on Thursday, reversing all the losses from the previous trading session. The company's shares oscillated between $2.15 and $2.26 before closing the day at $2.23. A total of 1.68 million shares were traded, which is below the daily average volume of 2.58 million. The company's shares have gained 2.06% in the last three trading sessions and 14.10% in the previous three months, outperforming the S&P 500, which has lost 0.32% and has gained 4.20% during the respective periods. Further, Galena Biopharma Inc.'s stock is trading above its 50-day and 200-day moving averages of $2.18 and $2.12, respectively. A free report on GALE can be accessed by registering at: http://www.AAAResearchReports.com/GALE110113.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: email@example.com
Morning Research: Ariad Pharma Inc., MannKind Corp., Novavax Inc., and Galena Biopharma Inc.
Press spacebar to pause and continue. Press esc to stop.